2023年2月27日，和誉医药（港交所代码：02256）宣布，其自主研发的两款新一代抗肿瘤抑制剂，和已获中美双突破性疗法认定的CSF-1R抑制剂Pimicotinib（ABSK021）的药物发现及转化医学研究成果，以及其他两项临床前医学研究成果将在4月14日至19日于美国佛罗里达州奥兰多召开的AACR年会上以壁报的形式公布。

5项研究成果的摘要具体内容为：

Title: Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 35
Poster Board Number: 19
Abstract Presentation Number: LB328

Title: Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 35
Poster Board Number: 8
Abstract Presentation Number: LB317

Title: A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 35
Poster Board Number: 7
Abstract Presentation Number: LB316

Title: A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 35
Poster Board Number: 20
Abstract Presentation Number: LB329

Title: Discovery and characterization of ABSK112, a next-generation and potential best-in-class EGFR Exon20 mutant inhibitor with superior selectivity and brain penetration ability
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 35
Poster Board Number: 18
Abstract Presentation Number: LB327

关于AACR
美国癌症研究协会（AACR）年会是全球历史最悠久、规模最大的肿瘤研究学术会议之一。会议关注高质量肿瘤研究及创新的各个方面，是全球肿瘤研究的焦点，将汇集肿瘤领域的最前沿的研究成果。它涵盖了癌症研究领域的最新发现——从人口科学和预防，到癌症生物学、转化和临床研究，再到生存和宣传——并突出了来自世界各地机构的研究和医学领域最优秀人才的工作。